Abbott Laboratories ABT

Revenue Intelligence Report • 57 quarters of SEC filing data • Updated 2026-10-14 • Data through 2026-03-31

Abbott Laboratories's latest quarterly revenue is $11.2B for the period ending 2026-03-31. The model projects $48.5B across the next four quarters (+7.4% versus the preceding four quarters). The forecast uses SG&A data; model selection and estimation exclude the latest quarter, whose retrospective holdout error is 3.1%. These are statistical associations, not estimates of the causal effect of spending.

Investment Thesis

The ARDL forecast is based on reported revenue and SG&A data through 2026-03-31. Training MAPE measures fit to historical data; the separately reported holdout error measures a withheld quarter. Spending coefficients describe associations and do not establish causation.

Next 4 Quarters
$48.5B
+7.4% YoY
SG&A Elasticity
1.16x
Training Fit
3.8% MAPE
Retrospective holdout (Q1 FY2026): The model predicted $11.50B vs the actual $11.16B — an error of 3.1%.
Retrospective one-quarter holdout: model fitting and selection exclude this quarter. Historical inputs use the latest available restatements, so this is not a preserved real-time forecast.
Note: Abbott Laboratories does not report R&D expenses separately. The model uses the available expense measure without a separate R&D term.

Revenue Forecast

ABT Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q1 FY2026
Period end 2026-03-31		 $11.50B $11.16B $10.43B–$12.69B +11.1% ✓ In range
Q2 FY2026
Period end 2026-06-30		 $11.77B $10.24B–$13.52B +5.6%
Q3 FY2026
Period end 2026-09-30		 $11.98B $10.11B–$14.20B +5.4%
Q4 FY2026
Period end 2026-12-31		 $12.28B $10.09B–$14.93B +7.1%
Q1 FY2027
Period end 2027-03-31		 $12.46B $10.01B–$15.51B +11.6%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Abbott Laboratories's systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Jan–Mar) 0.9533 -4.7% -4.7% below trend 13
FQ2 (Apr–Jun) 1.012 +1.2% In line with trend 13
FQ3 (Jul–Sep) 0.995 -0.5% In line with trend 13
FQ4 (Oct–Dec) 0.9957 -0.4% In line with trend 13

Spending and Revenue

ABT Spending Timing
Reading this chart: Each line shows the cumulative revenue association with a 1% change in spending over subsequent quarters. These estimates describe historical associations and do not establish causation.

Time-Varying Spending Associations

Time-varying analysis: A penalized spline model (GAM) tracks the association between log spending and log revenue over 57 quarters. Its coefficients describe conditional historical associations, not causal returns on spending.
Current SG&A elasticity: 0.4917x
The model-term chart shows relative absolute term magnitudes. Its percentages are not shares of revenue or causal contributions to growth.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. SEC source data. Forecast model: ARDL; spending associations: ARDL (log-log) with 57 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

GEHC REGN INCY IDXX ISRG MRK DXCM MCK